Navamedic ASA Asset Resilience Ratio
Navamedic ASA asset resilience ratio. Navamedic ASA (NAVA) has an Asset Resilience Ratio of 1.62% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Navamedic ASA fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Navamedic ASA (2008–2025)
Asset resilience ratio of Navamedic ASA from 2008 to 2025. This chart shows how Navamedic ASA's Asset Resilience Ratio has changed over time. Read total liabilities of Navamedic ASA for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Navamedic ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Navamedic ASA.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 0% |
| Short-term Investments | Nkr11.18 Million | 1.62% |
| Total Liquid Assets | Nkr11.18 Million | 1.62% |
Asset Resilience Insights
- Limited Liquidity: Navamedic ASA maintains only 1.62% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Navamedic ASA Industry Peers by Asset Resilience Ratio
Compare Navamedic ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hanmi Science
KO:008930 |
Medical Distribution | 0.04% |
|
Paragon Care Ltd
AU:PGC |
Medical Distribution | 0.00% |
|
TELES Informationstechnologien AG
XETRA:TLIK |
Medical Distribution | 0.37% |
|
Sigma Healthcare Ltd
AU:SIG |
Medical Distribution | 0.03% |
|
Ebos Group Ltd
AU:EBO |
Medical Distribution | 0.00% |
|
Mayne Pharma Group Ltd
AU:MYX |
Medical Distribution | 4.00% |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3 |
Medical Distribution | 4.48% |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607 |
Medical Distribution | 3.91% |
Navamedic ASA Asset Resilience Ratio by Year (2008–2025)
Navamedic ASA asset resilience ratio by year from 2008 to 2025. The table below shows the annual Asset Resilience Ratio data for Navamedic ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.04% | Nkr81.87 Million ≈ $8.61 Million |
Nkr741.75 Million ≈ $78.05 Million |
+0.40pp |
| 2024-12-31 | 10.64% | Nkr52.27 Million ≈ $5.50 Million |
Nkr491.24 Million ≈ $51.69 Million |
+3.34pp |
| 2023-12-31 | 7.30% | Nkr38.29 Million ≈ $4.03 Million |
Nkr524.30 Million ≈ $55.17 Million |
-9.78pp |
| 2022-12-31 | 17.08% | Nkr65.39 Million ≈ $6.88 Million |
Nkr382.77 Million ≈ $40.28 Million |
+1.15pp |
| 2021-12-31 | 15.94% | Nkr52.62 Million ≈ $5.54 Million |
Nkr330.18 Million ≈ $34.74 Million |
+14.11pp |
| 2020-12-31 | 1.83% | Nkr4.76 Million ≈ $501.20K |
Nkr260.04 Million ≈ $27.36 Million |
+9.38pp |
| 2019-12-31 | -7.55% | Nkr-14.13 Million ≈ $-1.49 Million |
Nkr187.06 Million ≈ $19.68 Million |
-12.70pp |
| 2018-12-31 | 5.14% | Nkr11.05 Million ≈ $1.16 Million |
Nkr214.73 Million ≈ $22.60 Million |
-7.09pp |
| 2017-12-31 | 12.23% | Nkr30.25 Million ≈ $3.18 Million |
Nkr247.27 Million ≈ $26.02 Million |
+2.92pp |
| 2016-12-31 | 9.32% | Nkr26.80 Million ≈ $2.82 Million |
Nkr287.67 Million ≈ $30.27 Million |
-54.54pp |
| 2008-12-31 | 63.86% | Nkr101.95 Million ≈ $10.73 Million |
Nkr159.65 Million ≈ $16.80 Million |
-- |
About Navamedic ASA
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition… Read more